Prescribing & Filling

Prescribe the Highest Level of Opioid Overdose Treatment

When you prescribe opioids, help ensure your patients have the highest dose emergency response option available: REZENOPY™ Nasal Spray, delivering 10 mg naloxone, the highest FDA-approved dose per nasal spray.1*

*The clinical significance of a higher dose is currently unknown.

Highest Dose Available

REZENOPY delivers 10 mg per nasal spray to address abuse of today’s potent opioids.

Download Profile

Quick Start Guide

A step-by-step guide to help patients and caregivers  administer REZENOPY. 

Download Guide

Ready to Prescribe?

Access co-prescribing materials, patient education, ordering information and product support. 

See All Resources

A New Concentration for Evolving Challenges 

As the opioid landscape shifts, so does the need for comprehensive emergency response options. Since 2013, synthetic opioids like fentanyl have become the primary driver of opioid overdose deaths, with fentanyl-related deaths increasing 23-fold between 2013 and 2023.2  Fentanyl is 50 to 100 times more potent than morphine,3 creating unprecedented challenges for overdose reversal.  

Hand holding a 10 mg Rezenopy (naloxone HCl) nasal spray device

Why a Higher Dose Matters

Research consistently demonstrates that fentanyl overdoses present unique pharmacological challenges:

  • Rapid Receptor Occupancy – Fentanyl’s rapid onset requires naloxone to out-compete high numbers of occupied opioid receptors in the CNS.7
  • Multiple Doses Often Needed – Emergency departments are reporting increasing use of multiple naloxone administrations for opioid overdoses, a trend occurring alongside the rise of fentanyl and other synthetic opioids.5
  • Higher Doses Recommended – Research indicates higher naloxone doses may be needed for potent synthetic opioid overdoses6

The scale of opioid misuse in the U.S. underscores the need for widely available, high-concentration reversal agents at every point of care

Infographic showing opioid misuse statistics.

High-dose REZENOPY enables rapid reversal of potent opioid overdoses and may reduce the need for repeat administration.

The clinical significance of a higher dose is currently unknown.

Indications & Usage

REZENOPY™ (naloxone HCl) 10 mg nasal spray is indicated for opioid antagonist for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for patients who often require multiple doses of lower-strength naloxone for stabilization in emergency situations. It is not a substitute for emergency medical care.1 Please see Important Safety Information below.

Male doctor in a white coat and blue gloves explaining a bottle of prescription medication to a female patient in a clinic.

Actor portrayal, not actual patient

Leadership Perspectives

“The addition of a large national health plan, combined with our GPO agreements covering more than 5,000 institutions, significantly enhances our ability to reach patients, healthcare providers and first responders across the country.”

Narasimhan Mani, President & Co-CEO, Scienture Holdings

“With institutional reach across hospitals, EMS providers and rehabilitation centers, and an expanding commercial team, we are executing on a comprehensive market access strategy designed to maximize awareness, availability and adoption of REZENOPY nationwide. We believe REZENOPY has the potential to become an important tool in the fight against opioid overdose and help expand access to life-saving intervention when every second counts.”

Shankar Hariharan, Executive Chairman & Co-CEO, Scienture Holdings

“We are excited about this upcoming launch and confident that bringing the highest-strength 10 mg naloxone product to market will address a critical and growing unmet need.”

Shankar Hariharan, Executive Chairman & Co-CEO, Scienture Holdings

“Our nasal drug delivery team has created a nasal spray that is quick and simple to administer, and which has the potential to prevent unnecessary overdoses across the United States.”

Milton Boyer, CEO, Kindeva Drug Delivery

“REZENOPY represents a significant advancement in overdose response as the highest-strength naloxone available on the market at 10 mg. It is intended for patients who often require multiple doses of lower-strength naloxone for stabilization in emergency situations.”

Narasimhan Mani, President & Co-CEO, Scienture Holdings

Helpful Information for Prescribers & Pharmacists

Downloadable Resources
Frequently Asked Questions

References

  1. REZENOPY™ (naloxone HCl) nasal spray 10 mg [prescribing information]. Commack, NY; Scienture, LLC 2025.
  2. Are fentanyl overdose deaths rising in the US?, USAFacts website. Available at: https://usafacts.org/articles/are-fentanyl-overdose-deaths-rising-in-the-us. Accessed March 2026.
  3. Fentanyl (2025) National Institute on Drug Abuse website. Available at: https://nida.nih.gov/research-topics/fentanyl. Accessed: March 2026.
  4. Huang H, Chen Y, Chen X, et al. Drug-induced heart failure: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. Frontiers in Pharmacology. 2024. Available at: https://www.frontiersin.org/articles/10.3389/fphar.2024.1523136. Accessed March 2026.
  5. Rzasa Lynn R, Galinkin JL, McClain M, Alfieri T. Use of multiple naloxone administrations in the emergency department: A retrospective claims-based analysis. Journal of Emergency Medicine. 2025;79:111–122. Available at: https://jem-journal.com/retrieve/pii/S0736467925001696. Accessed March, 2026.
  6. Moss RB, Carlo DJ. Higher doses of naloxone are needed in the synthetic opioid era. Substance Abuse Treatment, Prevention, and Policy. 2019;14:6. Available at: https://doi.org/10.1186/s13011-019-0195-4. Accessed March 2026
  7. Strauss DG, Li Z, Chaturbedi A, Chakravartula S, Samieegohar M, Mann J, Nallani SC, Prentice K, Shah A, Burkhart K, Boston J, Fu YA, Dahan A, Zineh I, Florian JA. Intranasal Naloxone Repeat Dosing Strategies and Fentanyl Overdose: A Simulation-Based Randomized Clinical Trial. JAMA Netw Open. 2024 Jan 2;7(1):e2351839. doi: 10.1001/jamanetworkopen.2023.51839. PMID: 38261323; PMCID: PMC10807299.